Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2010

View Archived Issues

Interim results from phase I study on anti-ALK-1 mAb PF-03446962 in solid tumors presented

Preliminary phase I data on HDAC inhibitor CHR-3996 in advanced solid tumors disclosed

Banyu discovers Wee1 kinase inhibitors for cancer therapy

Janssen claims new fatty acid amide hydrolase inhibitors

AstraZeneca presents new antimycobacterial agents

Euroscreen claims new GPR43 agonists/partial agonists

Novel DDAH inhibitors disclosed by German scientists

GPR119 agonist AS-1535907 regulates insulin expression and pancreatic beta-cell mass in vivo

CRASH-2 findings support use of tranexamic acid in trauma patients with significant bleeding

Genetic profiles of patients responding to antihypertensive rostafuroxine identified

InNexus develops protein for potential use in AMD

Sangamo receives funding to develop Parkinson's disease treatment

Phosphagenics to assess dosing regimen for its transdermal oxycodone patch

GSK and Genmab amend ofatumumab agreement

Evotec starts phase II study of EVT-101 in treatment-resistant depression

FDA grants Cyclacel orphan designation for sapacitabine in AML and MDS

Final data from Zadaxin study show enhanced immune response after vaccination

Oxygen reports porcine animal model results for Oxycyte in decompression sickness

Sanofi-aventis and JDRF partner for type 1 diabetes therapeutics

MorphoSys achieves milestone in antibody partnership with Novartis

Phase III study of Avastin combined with chemotherapy meets primary endpoint

Javelin to become fully owned subsidiary of Hospira

Intercell reports results from phase II trial of Vaccine Enhancement Patch

Lilly set to acquire Alnara and its PERT therapy liprotamase

Otsuka and MethylGene extend collaboration for kinase inhibitors in ocular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...